Arthur Roach

50 Broadway
London, ENG SW1H0DB, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Public involvement in the design of a complex neurosurgical clinical trial (the GDNF trial) and an associated support package: reflections and recommendations.

Public involvement in the design of a complex neurosurgical clinical trial (the GDNF trial) and an associated support package: reflections and recommendations.

Journal: Trials

Published: July 27, 2025

Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop.

Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop.

Journal: Journal of Parkinson's disease

Published: February 17, 2025

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

Journal: Journal of Parkinson's disease

Published: September 17, 2019

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

Journal: Journal of Parkinson's disease

Published: July 16, 2019

Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease.

Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease.

Journal: Clinical and translational science

Published: October 09, 2018

Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease.

Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease.

Journal: Neuropathology and applied neurobiology

Published: April 21, 2015

Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.

Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.

Journal: Brain : a journal of neurology

Published: March 23, 2013

Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor.

Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor.

Journal: Pharmacology, biochemistry, and behavior

Published: November 11, 2012

Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.

Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.

Journal: Parkinsonism & related disorders

Published: August 16, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026